Improvement of the noradrenergic symptom cluster following treatment with milnacipran

Neuropsychiatric Disease and Treatment

Volumn 7, Issue SUPPL., 2011, Pages 21-27

  Kasper, Siegfried ^a   Meshkat, Diana ^a   Kutzelnigg, Alexandra ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Depression; Milnacipran; Noradrenergic neurotransmission; Serotonin and norepinephrine reuptake inhibitors (SNRIs); Social adaptation self evaluation scale (SASS); Social functioning

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; DULOXETINE; FLUOXETINE; MILNACIPRAN; PAROXETINE; PLACEBO; REBOXETINE; VENLAFAXINE;

COGNITION; CONCENTRATION LOSS; DEPRESSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FATIGUE; HUMAN; LATENT PERIOD; MAJOR DEPRESSION; MENTAL CAPACITY; MOTOR DYSFUNCTION; NEUROTRANSMISSION; NORADRENERGIC SYSTEM; REMISSION; RETARDATION; REVIEW; SLEEP DISORDER; SOCIAL ADAPTATION; SOCIAL DISABILITY; SOCIAL INTERACTION; SPEECH DISORDER; SYMPTOMATOLOGY; THOUGHT DISORDER;

EID: 80955139846     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S19615     Document Type: Review

References (46)

1. Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry. 1998;59(Suppl 14): 11-14.
2. Leonard BE. Noradrenaline in basic models of depression. Eur Neuropsychopharmacol. 1997;7(Suppl 1):S11-S16.
3. Bymaster FP, McNamara RK, Tran PV. New approaches to developing antidepressants by enhancing monoaminergic neurotransmission. Expert Opin Investig Drugs. 2003;12:531-543.
4. Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry. 2002;52:740-748.
5. Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 2008;69(Suppl E1):4-7.
6. Kasper S, Pail G. Milnacipran: a unique antidepressant? Neuropsychiatr Dis Treat. 2010;6:23-31.
7. Carlsson A, Corrodi H, Fuxe K, Hökfelt T. Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-meta-tyramine. Eur J Pharmacol. 1969;5:357-366.
8. Healy D, McMonagle T. The enhancement of social functioning as a therapeutic principle in the management of depression. J Psychopharmacol. 1997;11(Suppl 4):S25-S31.
9. Katon W. The impact of depression on workplace functioning and disability costs. Am J Manag Care. 2009;15(Suppl 11):S322-S327.
10. Weissman MM, Klerman GL, Paykel ES, et al. Treatment effects on the social adjustment of depressed patients. Arch Gen Psychiatry. 1974;30:771-778.
11. Paykel ES, Weissman MM, Prusoff BA. Social maladjustment and severity of depression. Compr Psychiatry. 1978;19:121-128.
12. Hays RD, Wells KB, Sherbourne CD, et al. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry. 1995;52:11-19.
13. Leader JB, Klein DN. Social adjustment in dysthymia, double depression and episodic major depression. J Affect Disord. 1996;37:91-101.
14. Tse WS, Bond AJ. The impact of depression on social skills. J Nerv Ment Dis. 2004;192:260-268.
15. Bech P. Social functioning: should it become an endpoint in trials of antidepressants? CNS Drugs. 2005;19:313-324.
16. Daly EJ, Trivedi MH, Wisniewski SR, et al. Health-related quality of life in depression: a STARD report. Ann Clin Psychiatry. 2010;22: 43-55.
17. Weissman MM, Olfson M, Gameroff MJ, et al. A comparison of three scales for assessing social functioning in primary care. Am J Psychiatry. 2001;158:460-466.
18. Bosc M, Dubini A, Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur Neuropsychopharmacol. 1997;7(Suppl 1):S57-S70.
19. Bosc M. Assessment of social functioning in depression. Compr Psychiatry. 2000;41:63-69.
20. Healy D. Reboxetine: its effects as measured by the Social Adaptation Self- evaluation Scale. Acta Psychiatr Scand. 2000;402(Suppl): 45-51.
21. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
22. Tse WS, Bond AJ. Difference in serotonergic and noradrenergic regulation of human social behaviours. Psychopharmacology (Berl). 2002;159:216-221.
23. Weissman MM, Bothwell S. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry. 1976;33:1111-1115.
24. Tse WS, Bond AJ. Reboxetine promotes social bonding in healthy volunteers. J Psychopharmacol. 2003;17:189-195.
25. Tse WS, Bond AJ. Noradrenaline might enhance assertive human social behaviours: an investigation in a flatmate relationship. Pharmacopsychiatry. 2006;39:175-179.
26. Paykel ES, Weissman MM. Social adjustment and depression. A longitudinal study. Arch Gen Psychiatry. 1973;28:659-663.
27. Dubini A, Bosc M, Polin V. Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur Neuropsychopharmacol. 1997;7(Suppl 1):S49-S55.
28. Dubini A, Bosc M, Polin V. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol. 1997;11(Suppl 4): S17-S23.
29. Massana J, Möller HJ, Burrows GD, Montenegro RM. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol. 1999;14:73-80.
30. Keller M. Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS). Gen Hosp Psychiatry. 2001;23:15-19.
31. Gorenstein C, Andrade L, Moreno RA, Artes R. Social adjustment in depressed patients treated with venlafaxine and amitriptyline. Int Clin Psychopharmacol. 2002;17:171-175.
32. Mbaya P. Safety and efficacy of high dose of venlafaxine XL in treatment resistant major depression. Hum Psychopharmacol. 2002;17: 335-339.
33. Pjrek E, Willeit M, Praschak-Rieder N, et al. Treatment of seasonal affective disorder with duloxetine: an open-label study. Pharmacopsychiatry. 2008;41:100-105.
34. Koch S, Hemrick-Luecke SK, Thompson LK, et al. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology. 2003;45: 935-944.
35. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10:732-747.
36. Yoshida K, Takahashi H, Higuchi H, et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry. 2004;161:1575-1580.
37. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol. 1980;10:189-209.
38. Hindmarch I, Rigney U, Stanley N, Briley M. Pharmacodynamics of milnacipran in young and elderly volunteers. Br J Clin Pharmacol. 2000;49:118-125.
39. Sechter D, Vandel P, Weiller E, et al. A comparative study of milnacipran and paroxetine in outpatients with major depression. J Affect Disord. 2004;83:233-236.
40. Puech A, Montgomery SA, Prost JF, et al. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol. 1997;12: 99-108.
41. Kasper S. The place of milnacipran in the treatment of depression. Hum Psychopharmacol. 1997;12:S135-S141.
42. Fukuchi T, Kanemoto K. Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case-control study. Int Clin Psychopharmacol. 2002;17: 53-58.
43. Lemoine P, Faivre T. Subjective and polysomnographic effects of milnacipran on sleep in depressed patients. Hum Psychopharmacol. 2004;19:299-303.
44. Briley M, Moret C. Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors. Neuropsychiatr Dis Treat. 2010;6:647-655.
45. Ueda N, Yoshimura R, Houjo T, et al. Effects of milnacipran on social adaptation in patients with depression. Rinshyo Seisin Yakuri. 2008;11: 273-279.
46. Ishida T, Inada Y, Kudo M, et al. Study on the clinical efficacy of milnacipran by using the Social Adaptation Self-evaluation Scale. Jap J Clin Psychopharmacol. 2010;13:77-83.